FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy

[MEDPAGE TODAY]( Oncology Update Tuesday, November 28, 2023 [FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy]( [FDA Approves First Therapy for Progressive Desmoid Tumors]( [Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomy]( [Mailing HPV Self-Sampling Kits to Patients Boosted Cervical Cancer Screening]( ADVERTISEMENT Exclusives & Features [Hospitals Say Some Medicare Advantage Plans Are Skirting CMS Rules]( [Days Before Surgery, Clerical Error Cuts Off Patient's Insurance]( [Evolving Overdose Crisis Shakes Previously Effective Treatments]( [FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.]( On May 25th, 2022, FDA approved a supplemental application for ivosidenib (Tibsovo; Servier) extending the indication in patients with newly-diagnosed IDH1-mutated acute myeloid leukemia (AML) in... [READ MORE]( [Modulating gut microbiota prevents anastomotic leak to reduce local implantation and dissemination of colorectal cancer cells after surgery.]( PURPOSE: Anastomotic leak (AL) is a major complication in colorectal cancer (CRC) surgery, and consists of the leakage of intestinal content through a poorly healed colonic wound. CRC recurrence... [READ MORE]( [Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.]( BACKGROUND: Single-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable disease. The primary... [READ MORE]( [Impact of an automated, remote monitoring and coaching intervention in reducing hospice cancer family caregiving burden: A multisite randomized controlled trial.]( BACKGROUND: Care for those with life-limiting cancer heavily involves family caregivers who may experience significant physical and emotional burden. The purpose of this study was to test the impact... [READ MORE]( [It takes more than rainbows: Supporting sexual and gender minority patients with trauma-informed cancer care.]( BACKGROUND/PURPOSE: The American Society of Clinical Oncology has called for an increased priority to improve cancer care for sexual and gender minority (SGM) populations because of heightened risk... [READ MORE]( [A Property of Everyday Health group]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2023-11-28&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011